U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
A new diagnosis of type 2 diabetes may be linked to a subsequent increased risk of developing some obesity-related cancers, according to findings presented at the European Congress on Obesity (ECO) 20...
Researchers have identified the Alternative Healthy Eating Index as the most effective dietary pattern for promoting healthy aging, with plant-based foods and moderate healthy animal proteins supporting cognitive, physical, and mental health into later years.
"Partial weight regain after substantial weight loss was associated with a less favorable cardiovascular risk profile and an increased incidence of both microvascular and macrovascular diseases."